Fig. 1

Therapeutic efficacy of four different hUCMSCs infusion regimens on DLC rats. A Diagram of different hUCMSCs infusion regimens for DLC rats. NC: Negative control; DLC: Decompensated liver cirrhosis rats model; T-A: A single hUCMSCs infusion at week 5 of modeling in DLC rats; T-B: Triple hUCMSCs infusion (once a week) at week 5 of modeling in DLC rats; T-C: A single hUCMSCs infusion at week 8 of modeling in DLC rats; T-D: Triple hUCMSCs infusion (once a week) at week 8 of modeling in DLC rats; B The survival of rats was recorded from week 6 to the end of week 11(n = 12). C The ascites was measured at the end of week 11(n = 5). D Ratio of the liver weight to the body weight in rats at the end of week 11(n = 4). E Hydroxyproline content of liver tissues following different treatment regimens was measured by Commercial kit at the end of week 11(n = 4). F and G Hematoxylin and eosin (H&E) and Sirius red staining of liver sections (Bar = 100 μm). H The quantification analysis of Sirius red positive area by ImageJ (n = 3). Hematoxylin and eosin (H&E) and Sirius red staining of liver sections (Bar = 100 μm). I Serum levels of key enzymes related to liver function at the end of week 11(n = 4). Data are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, and ns (no statistical significance) (all p values were obtained by the Two-tailed Student’s Test)